Causes of Mitral Stenosis
Rheumatic heart disease is the predominant cause of mitral stenosis, accounting for approximately 85% of all cases worldwide. 1
Primary Etiologies
Rheumatic Heart Disease
- Most common cause globally (85% of cases) 1
- Results from rheumatic fever following group A β-hemolytic streptococcal infection 2
- Pathological features include:
Degenerative Mitral Stenosis
- Becoming increasingly prevalent in developed countries with aging populations 1, 3
- Accounts for approximately 12% of mitral stenosis cases referred to hospitals 1
- Characterized by:
Congenital Mitral Stenosis
- Rare cause, mainly observed in infants and children 1
- Various subtypes include:
Uncommon Causes
Infective Endocarditis
- Active infection can cause valve obstruction through vegetations 5
- More commonly causes regurgitation than stenosis
Left Atrial Myxoma
- Can cause functional mitral stenosis by obstructing the mitral valve orifice 1
Ball Valve Thrombus
- Large thrombus in left atrium can obstruct mitral inflow 1
Severe Annular Calcification
- Can progress to cause stenosis, particularly in elderly patients 1, 3
- More common in patients >50 years of age 1
Mucopolysaccharidosis
- Rare metabolic disorder that can affect valve structure 1
Iatrogenic
- Rare complication following certain cardiac procedures
Age and Geographic Distribution Patterns
- Rheumatic MS tends to present in younger patients, including during pregnancy 1
- Degenerative MS is associated with increased age, more common in developed countries 1, 3
- Rheumatic heart disease remains highly prevalent in developing countries 2, 6
- Incidence of rheumatic fever had declined in Western countries but is seeing a resurgence due to immigration from non-industrialized countries 2
Clinical Implications
The etiology of mitral stenosis significantly impacts treatment options:
Understanding the underlying cause is essential for proper management and prognostication, as rheumatic and degenerative MS display significant differences in pathophysiology, prognosis, and disease progression 3